更新于：2024-12-22
NB-002(NeoLogics Bioscience)
更新于：2024-12-22
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
关联
1
项与 NB-002(NeoLogics Bioscience) 相关的临床试验Phase 1a/1b, First-in-Human, Open Label, Dose Escalation and Dose Expansion Study of NB002, a Multifunctional TIM-3 Blocking Antibody, in Subjects With Advanced or Metastatic Solid Tumors
100 项与 NB-002(NeoLogics Bioscience) 相关的临床结果
登录后查看更多信息
100 项与 NB-002(NeoLogics Bioscience) 相关的转化医学
登录后查看更多信息
100 项与 NB-002(NeoLogics Bioscience) 相关的专利（医药）
登录后查看更多信息
11
项与 NB-002(NeoLogics Bioscience) 相关的文献（医药）2024-09-01COLLOIDS AND SURFACES B-BIOINTERFACES
Fabrication of photo-induced molecular superoxide radical generator for highly efficient therapy against bacterial wound infection
Article
作者: Yang, Na ; Yang, Xiaofei ; Nawaz, Muhammad Azhar Hayat ; Yu, Cong ; Han, Wenzhao ; Song, Shuang ; He, Di ; Li, Ying
The pressing need for highly efficient antibacterial strategies arises from the prevalence of microbial biofilm infections and the emergence of rapidly evolving antibiotic-resistant strains of pathogenic bacteria. Photodynamic therapy represents a highly efficient and compelling antibacterial approach, offering promising prospects for effective control of the development of bacterial resistance. However, the effectiveness of many photosensitizers is limited due to the reduced generation of reactive oxygen species (ROS) in hypoxic microenvironment, which commonly occur in pathological conditions such as inflammatory and bacteria-infected wounds. Herein, we designed and prepared two phenothiazine-derived photosensitizers (NB-1 and NB-2), which can effectively generate superoxide anion radicals (O2●-) through the type I process. Both photosensitizers demonstrate significant efficacy in vitro for the eradication of broad-spectrum bacteria. Moreover, NB-2 possesses distinct advantages including strong membrane binding and strong generation of O2●-, rendering it an exceptionally efficient antibacterial agent against mature biofilms. In addition, laser activated NB-2 could be applied to treat MRSA-infected wound in vivo, which offers new opportunities for potential practical applications.
2018-04-01Chemistry & biodiversity3区 · 化学
Design, Synthesis, and Anti‐HIV ‐1 Evaluation of a Novel Series of 1,2,3,4‐Tetrahydropyrimidine‐5‐Carboxylic Acid Derivatives
3区 · 化学
Article
作者: Saghaie, Lotfollah ; Sepehri, Saghi ; Memarian, Hamid R. ; Aghasadeghi, Mohammad R. ; Sadat, Mehdi ; Zabihollahi, Rezvan ; Soleymani, Sepehr ; Fassihi, Afshin
A series of tetrahydropyrimidine derivatives (2a – 2l) were designed, synthesized, and screened for anti‐HIV‐1 properties based on the structures of HIV‐1 gp41 binding site inhibitors, NB‐2 and NB‐64. A computational study was performed to predict the pharmacodynamics, pharmacokinetics, and drug‐likeness features of the studied molecules. Docking studies revealed that the carboxylic acid group in the molecules forms salt bridges with either Lys574 or Arg579. Physiochemical properties (e.g., molecular weight, number of hydrogen bond donors, number of hydrogen bond acceptors, and number of rotatable bonds) of the synthesized compounds confirmed and exhibited that these compounds were within the range set by Lipinski's rule of five. Compounds 2e and 2k with 4‐chlorophenyl substituent and 4‐methylphenyl group at C(4) position of the tetrahydropyrimidine ring was the most potent one among the tested compounds. This suggests that these compounds may serve as leads for development of novel small‐molecule HIV‐1 inhibitors.
2017-08-01Pharmacological reports : PR4区 · 医学
Synthesis and in vitro anticancer activity of new 2-thioxo-oxazolidin-4-one derivatives
4区 · 医学
Article
作者: de Lima, Maria do Carmo Alves ; da Rocha Pitta, Maira Galdino ; Pereira, Michelly Cristiny ; da Rocha Pitta, Marina Galdino ; de Sena, Wanessa Layssa Batista ; da Cruz Amorim, Cezar Augusto ; de Oliveira, Jamerson Ferreira ; Campos, Júlia Furtado ; de Melo Rêgo, Moacyr Jesus Barreto ; de Barros Martins, Caio Gomes ; da Rocha Pitta, Ivan
BACKGROUND:
Oxazolidinones derivatives exhibit different biological properties, including anticancer activity. This work aimed to investigate the anticancer potential of five novel 2-Thioxo-oxazolidin-4-one derivatives.
METHODS:
Cytotoxicity assays were performed in human peripheral blood mononuclear cells (PBMCs) from healthy individuals and seven tumor cell lines. Apoptosis detection and cell cycle were evaluated by flow cytometry and the expression of genes involved in cell death processes by Real-Time PCR.
RESULTS:
All oxazolinedione derivatives were not cytotoxic in PBMCs. NB-5 showed the best results in cancer cells, inhibiting the growth of all tumor cell lines tested. NB-4 exhibited the highest cytotoxicity in Jurkat cells (IC50=15.19μM) and NB-3 showed better anticancer effects in HL-60 (17.84μM). Only NB-4 significantly induced apoptosis in acute leukemia cells (p=0.001). All compounds caused a significant increase in expression of pro-apoptotic gene BID (p<0.05) and BECN1 (p<0.05). NB-3 significantly modulated the expression of RIPK3 (p=0.02) and DDIT3 (p=0.014), while NB-2 induced an increase of CDKN1A (p=0.03) and NB-4 induced PPARγ gene (p=0.0006).
CONCLUSION:
NB-5 showed antitumor effects in solid and hematopoietic cancer cells, while other derivatives produced higher activity against hematopoietic cells. In acute leukemia cells, oxazolidinone derivatives modulated the expression of genes involved in apoptosis, ER stress, necroptosis and inflammation.
2
项与 NB-002(NeoLogics Bioscience) 相关的新闻（医药）2023-05-19
100 项与 NB-002(NeoLogics Bioscience) 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性实体瘤 | 临床1期 | - | 2023-10-01 | |
| 肿瘤 | 临床1期 | 中国 | 2023-04-04 | |
| 血液肿瘤 | 临床前 | 中国 | 2023-04-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用